WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H328607
CAS#: 155648-60-5(monohydrate)
Description: Minodronic Acid Monohydrate (also known as Bonoteo, YM-529, and YH-529) is a nitrogen-containing bisphosphonate that has a greater inhibitory effect on bone resorption. Mindodronic Acid is used for the treatment of osteoporosis.
Hodoodo Cat#: H328607
Name: Minodronic Acid Monohydrate
CAS#: 155648-60-5(monohydrate)
Chemical Formula: C9H14N2O8P2
Exact Mass: 0.00
Molecular Weight: 340.165
Elemental Analysis: C, 31.78; H, 4.15; N, 8.24; O, 37.63; P, 18.21
Related CAS #: 155648-60-5(monohydrate) 180064-38-4 (acid),
Synonym: Minodronic Acid Monohydrate; ONO-5920; YM-529; YH-529; BPH-261; ONO 5920; YM 529; YH 529; BPH 261; ONO5920; YM529; YH529; BPH261; Bonoteo
IUPAC/Chemical Name: (1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)bis(phosphonic acid) hydrate
InChi Key: GPAPAOGRNKUFGH-UHFFFAOYSA-N
InChi Code: InChI=1S/C9H12N2O7P2.H2O/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8;/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18);1H2
SMILES Code: OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=C2C=CC=CN21.[H]O[H]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# 180064-38-4(Minodronic Acid) 155648-60-5(Minodronic Acid Monohydrate)
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 340.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Tanaka M, Mori H, Kawabata K, Mashiba T. Minodronic acid ameliorates vertebral bone strength by increasing bone mineral density in 9-month treatment of ovariectomized cynomolgus monkeys. Bone. 2016 Jul;88:157-64. doi: 10.1016/j.bone.2016.05.001. Epub 2016 May 4. PubMed PMID: 27155564.
2: Kitamura N, Shiraiwa H, Inomata H, Nozaki T, Ikumi N, Sugiyama K, Nagasawa Y, Karasawa H, Iwata M, Matsukawa Y, Takei M. Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis. Int J Rheum Dis. 2016 Mar 1. doi: 10.1111/1756-185X.12844. [Epub ahead of print] PubMed PMID: 26929019.
3: Imai A, Matsunami K, Ichigo S, Takagi H. Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study. Gynecol Endocrinol. 2016;32(3):250-2. doi: 10.3109/09513590.2015.1112783. Epub 2015 Nov 20. PubMed PMID: 26503621.
4: Zhou Y, He X, Li H, Ni Y, Xu M, Sattar H, Chen H, Li W. Pharmacokinetics and tolerability of minodronic acid tablets in healthy Chinese subjects and food and age effects on the pharmacokinetics. Clin Ther. 2015 Apr 1;37(4):869-76. doi: 10.1016/j.clinthera.2015.01.015. Epub 2015 Mar 5. PubMed PMID: 25748293.
5: Tanaka M, Matsugaki A, Ishimoto T, Nakano T. Evaluation of crystallographic orientation of biological apatite in vertebral cortical bone in ovariectomized cynomolgus monkeys treated with minodronic acid and alendronate. J Bone Miner Metab. 2016 Mar;34(2):234-41. doi: 10.1007/s00774-015-0658-2. Epub 2015 Apr 3. PubMed PMID: 25837430.
6: Iwamoto J, Seki A, Sato Y. Effect of combined teriparatide and monthly minodronic acid therapy on cancellous bone mass in ovariectomized rats: a bone histomorphometry study. Bone. 2014 Jul;64:88-94. doi: 10.1016/j.bone.2014.04.003. Epub 2014 Apr 13. PubMed PMID: 24727162.
7: Tanaka M, Mori H, Kayasuga R, Ochi Y, Yamada H, Kawada N, Kawabata K. Effect of intermittent and daily regimens of minodronic Acid on bone metabolism in an ovariectomized rat model of osteoporosis. Calcif Tissue Int. 2014 Aug;95(2):166-73. doi: 10.1007/s00223-014-9876-1. Epub 2014 Jun 6. PubMed PMID: 24903232.
8: Yang Y, Liu C, Zhang Y, Zhou L, Zhong D, Chen X. On-cartridge derivatization coupled with solid-phase extraction for the ultra-sensitive determination of minodronic acid in human plasma by LC-MS/MS method. J Pharm Biomed Anal. 2015 Oct 10;114:408-15. doi: 10.1016/j.jpba.2015.05.038. Epub 2015 Jun 18. PubMed PMID: 26117452.
9: Kimoto A, Tanaka M, Nozaki K, Mori M, Fukushima S, Mori H, Shiroya T, Nakamura T. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment. Bone. 2013 Jul;55(1):189-97. doi: 10.1016/j.bone.2013.02.013. Epub 2013 Feb 26. PubMed PMID: 23486179.
10: Tanaka M, Mori H, Kawabata K. Attenuation of Antiresorptive Action in Withdrawal of Minodronic Acid for Three Months After Treatment for Twelve Months in Ovariectomized Rats. Calcif Tissue Int. 2015 Oct;97(4):402-11. doi: 10.1007/s00223-015-0017-2. Epub 2015 Jun 6. PubMed PMID: 26048283.
